We are pleased to launch the first edition of the Pava Nutraceuticals Report, a new report series building on our consumer health research and dedicated to the European nutraceuticals market.

With the European market expected to grow from approximately USD 120–130 billion in 2025 to USD 215–230 billion by 2033, nutraceuticals remain one of the most attractive segments within consumer health. But growth alone does not explain where value is being created.

Increasing formulation complexity, evolving regulatory requirements, and persistent capacity constraints are shifting value toward specialized upstream players – a trend that is becoming increasingly visible in competitive positioning, valuation dynamics, and M&A activity across the market.

What You’ll Learn

• The Structural Setup of European Nutraceuticals: Discover the long-term growth drivers shaping the industry and why structural bottlenecks are creating sustainable competitive advantages for select market participants.
• Who Captures the Value: Explore how increasing complexity, technical expertise, and regulatory know-how are shifting economics toward specialized ingredient suppliers and CDMOs, creating clear winners within the value chain.
• The M&A Lens: Learn where capital is flowing, why upstream specialists are attracting growing investor interest, and what makes a nutraceutical business transaction-ready.

Why This Report Matters

For business owners, executives, investors, and strategic acquirers, the key question is no longer whether the market will continue to grow, but where future value will accrue and which companies are best positioned to capture it.

The report provides a strategic perspective on the trends, value creation dynamics, and M&A developments shaping the next phase of growth and consolidation in the European nutraceuticals market.

Complete the form below to request your copy of the Pava Nutraceuticals Report 2026.

Alternatively, connect directly with our Nutraceuticals specialists, Dr. Lars Veit, Martin Fuchs and Malte Striegler, to discuss strategic growth opportunities, M&A developments, and financing trends shaping the European nutraceuticals sector.

Our Pava Nutraceuticals Report 2026 is published solely in English.